About Fc receptor-like protein 2
Fc receptor-like protein 2 (FCRL2) is a protein
from Homo sapiens identified by UniProt accession
Q96LA5, 508 residues long.
MolForge cross-references it against 0 known binders and
47 disease associations.
Target properties
| Protein name | Fc receptor-like protein 2 |
| UniProt accession | Q96LA5 |
| Gene | FCRL2 |
| Organism | Homo sapiens |
| Length | 508 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (47)
Diseases linked to this target (Open Targets).
- multiple sclerosis · score 0.33
- neurodegenerative disease · score 0.31
- Alzheimer disease · score 0.31
- Parkinson disease · score 0.31
- lysosomal storage disease · score 0.31
- blood protein measurement · score 0.23
- coronary artery disease · score 0.16
- neuroinflammatory disorder · score 0.14
- Graves disease · score 0.10
- systemic lupus erythematosus · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q96LA5-F1 | alphafold | PREDICTED | 80.72 | — |
Amino-acid sequence (508 residues)
MLLWSLLVIF DAVTEQADSL TLVAPSSVFE GDSIVLKCQG EQNWKIQKMA YHKDNKELSV FKKFSDFLIQ SAVLSDSGNY FCSTKGQLFL WDKTSNIVKI KVQELFQRPV LTASSFQPIE GGPVSLKCET RLSPQRLDVQ LQFCFFRENQ VLGSGWSSSP ELQISAVWSE DTGSYWCKAE TVTHRIRKQS LQSQIHVQRI PISNVSLEIR APGGQVTEGQ KLILLCSVAG GTGNVTFSWY REATGTSMGK KTQRSLSAEL EIPAVKESDA GKYYCRADNG HVPIQSKVVN IPVRIPVSRP VLTLRSPGAQ AAVGDLLELH CEALRGSPPI LYQFYHEDVT LGNSSAPSGG GASFNLSLTA EHSGNYSCEA NNGLGAQCSE AVPVSISGPD GYRRDLMTAG VLWGLFGVLG FTGVALLLYA LFHKISGESS ATNEPRGASR PNPQEFTYSS PTPDMEELQP VYVNVGSVDV DVVYSQVWSM QQPESSANIR TLLENKDSQV IYSSVKKS
Explore Fc receptor-like protein 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets